Response of uveal metastases to alk inhibitors in alk-positive non-small-cell lung cancer

Amro Abdellatief, Julian R Molina, Jose S Pulido

Research output: Contribution to journalArticle

Abstract

Purpose: To present a case of uveal metastases in a patient with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer and the response to systemic ALK inhibitors. Methods: A retrospective case report. A 75-year-old nonsmoker who has ALK-positive left upper bronchus adenocarcinoma-developed uveal metastases during his course of treatment. Results: Initially, the patient's disseminated malignancy showed a significant response to crizotinib. However, because the bone metastases started progressing again and he developed bilateral ocular metastases, he was switched to ceritinib. After initiation of ceritinib therapy, the uveal melanomas have shown a significant decrease in thickness and no new lesions have developed. Conclusion: ALK inhibitors are an effective first-line treatment in patients with ALK-positive uveal metastases secondary to ALK-positive non-small-cell lung cancer. Despite the fact that crizotinib, a first-generation ALK inhibitor, is initially effective in dealing with non-small-cell lung cancer and its metastases, resistance to it seems to develop on a regular basis. A second-generation ALK inhibitor, such as ceritinib, is also effective in overcoming this resistance in treating those with ALK-positive uveal metastases.

Original languageEnglish (US)
Pages (from-to)37-40
Number of pages4
JournalRetinal Cases and Brief Reports
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
anaplastic lymphoma kinase
Bronchi
Adenocarcinoma
Therapeutics
Bone and Bones
ceritinib

Keywords

  • ALK translocation
  • Ceritinib
  • Crizotinib
  • Metastases
  • Non-small-cell lung cancer
  • Uveal

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Response of uveal metastases to alk inhibitors in alk-positive non-small-cell lung cancer. / Abdellatief, Amro; Molina, Julian R; Pulido, Jose S.

In: Retinal Cases and Brief Reports, Vol. 10, No. 1, 01.01.2016, p. 37-40.

Research output: Contribution to journalArticle

@article{e7e283199d6a4cc78b40d45dce5067d4,
title = "Response of uveal metastases to alk inhibitors in alk-positive non-small-cell lung cancer",
abstract = "Purpose: To present a case of uveal metastases in a patient with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer and the response to systemic ALK inhibitors. Methods: A retrospective case report. A 75-year-old nonsmoker who has ALK-positive left upper bronchus adenocarcinoma-developed uveal metastases during his course of treatment. Results: Initially, the patient's disseminated malignancy showed a significant response to crizotinib. However, because the bone metastases started progressing again and he developed bilateral ocular metastases, he was switched to ceritinib. After initiation of ceritinib therapy, the uveal melanomas have shown a significant decrease in thickness and no new lesions have developed. Conclusion: ALK inhibitors are an effective first-line treatment in patients with ALK-positive uveal metastases secondary to ALK-positive non-small-cell lung cancer. Despite the fact that crizotinib, a first-generation ALK inhibitor, is initially effective in dealing with non-small-cell lung cancer and its metastases, resistance to it seems to develop on a regular basis. A second-generation ALK inhibitor, such as ceritinib, is also effective in overcoming this resistance in treating those with ALK-positive uveal metastases.",
keywords = "ALK translocation, Ceritinib, Crizotinib, Metastases, Non-small-cell lung cancer, Uveal",
author = "Amro Abdellatief and Molina, {Julian R} and Pulido, {Jose S}",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/ICB.0000000000000190",
language = "English (US)",
volume = "10",
pages = "37--40",
journal = "Retinal Cases and Brief Reports",
issn = "1935-1089",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Response of uveal metastases to alk inhibitors in alk-positive non-small-cell lung cancer

AU - Abdellatief, Amro

AU - Molina, Julian R

AU - Pulido, Jose S

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose: To present a case of uveal metastases in a patient with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer and the response to systemic ALK inhibitors. Methods: A retrospective case report. A 75-year-old nonsmoker who has ALK-positive left upper bronchus adenocarcinoma-developed uveal metastases during his course of treatment. Results: Initially, the patient's disseminated malignancy showed a significant response to crizotinib. However, because the bone metastases started progressing again and he developed bilateral ocular metastases, he was switched to ceritinib. After initiation of ceritinib therapy, the uveal melanomas have shown a significant decrease in thickness and no new lesions have developed. Conclusion: ALK inhibitors are an effective first-line treatment in patients with ALK-positive uveal metastases secondary to ALK-positive non-small-cell lung cancer. Despite the fact that crizotinib, a first-generation ALK inhibitor, is initially effective in dealing with non-small-cell lung cancer and its metastases, resistance to it seems to develop on a regular basis. A second-generation ALK inhibitor, such as ceritinib, is also effective in overcoming this resistance in treating those with ALK-positive uveal metastases.

AB - Purpose: To present a case of uveal metastases in a patient with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer and the response to systemic ALK inhibitors. Methods: A retrospective case report. A 75-year-old nonsmoker who has ALK-positive left upper bronchus adenocarcinoma-developed uveal metastases during his course of treatment. Results: Initially, the patient's disseminated malignancy showed a significant response to crizotinib. However, because the bone metastases started progressing again and he developed bilateral ocular metastases, he was switched to ceritinib. After initiation of ceritinib therapy, the uveal melanomas have shown a significant decrease in thickness and no new lesions have developed. Conclusion: ALK inhibitors are an effective first-line treatment in patients with ALK-positive uveal metastases secondary to ALK-positive non-small-cell lung cancer. Despite the fact that crizotinib, a first-generation ALK inhibitor, is initially effective in dealing with non-small-cell lung cancer and its metastases, resistance to it seems to develop on a regular basis. A second-generation ALK inhibitor, such as ceritinib, is also effective in overcoming this resistance in treating those with ALK-positive uveal metastases.

KW - ALK translocation

KW - Ceritinib

KW - Crizotinib

KW - Metastases

KW - Non-small-cell lung cancer

KW - Uveal

UR - http://www.scopus.com/inward/record.url?scp=84954104550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954104550&partnerID=8YFLogxK

U2 - 10.1097/ICB.0000000000000190

DO - 10.1097/ICB.0000000000000190

M3 - Article

C2 - 26263240

AN - SCOPUS:84954104550

VL - 10

SP - 37

EP - 40

JO - Retinal Cases and Brief Reports

JF - Retinal Cases and Brief Reports

SN - 1935-1089

IS - 1

ER -